Fractyl Health (GUTS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by June 9, 2026.
Voting matters and shareholder proposals
Election of three directors: Marc Elia, Clive Meanwell, and Ian Sheffield, with board recommending a vote for each.
Ratification of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Provision for other business to be addressed as may properly come before the meeting.
Board of directors and corporate governance
Board slate includes Marc Elia, Clive Meanwell, and Ian Sheffield as nominees for election.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Fractyl Health
- Stockholders will vote on director elections and auditor ratification, with a focus on governance and transparency.GUTS
Proxy filing25 Apr 2026 - Pivotal study fully enrolled, strong results, cash runway into 2027, no capital raise planned.GUTS
Q4 202524 Mar 2026 - Revita sustains weight loss and safety post-GLP-1, with pivotal data and FDA milestones ahead.GUTS
Study result3 Feb 2026 - Q2 net loss narrowed, cash rose to $102.4M, and Revita gained FDA Breakthrough status.GUTS
Q2 20241 Feb 2026 - Revita offers a durable, minimally invasive solution for sustained weight and diabetes control.GUTS
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Revita and Rejuva aim to transform obesity and diabetes care with durable, root-cause therapies.GUTS
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Durable weight maintenance solutions advance with pivotal Revita and Rejuva milestones in 2025.GUTS
Chardan's 8th Annual Genetic Medicines Conference20 Jan 2026 - Q3 net loss was $23.2M, cash runway extends into Q4 2025, but going concern risk persists.GUTS
Q3 202414 Jan 2026 - Pivotal trial data and first-in-human gene therapy for metabolic disease expected in 2025.GUTS
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026